by The global epinephrine autoinjector market comprises devices that deliver injections of epinephrine or adrenaline to treat dangerous allergic reactions like anaphylaxis. Epinephrine autoinjectors make it easy for patients or caregivers to administer a life-saving dose during an allergic emergency without training. They are small prefilled devices designed for self-administration or administration by a caregiver through outer thigh intramuscular injection.
The Global Epinephrine Autoinjector Market Trends is estimated to be valued at US$ 2.50 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players: Key players operating in the epinephrine Global Epinephrine Autoinjector Market Trends are Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, and Kaleo. Mylan’s EpiPen auto injectors dominate the global market.
Growing demand: The growing prevalence of allergies such as food allergies and anaphylaxis is driving the demand for epinephrine autoinjectors globally. According to statistics, over 50 million Americans have food allergies.
Global expansion: Major players in the market are expanding their presence globally, especially in developing countries, through strategic collaborations and acquisitions to tap the growth opportunities. For instance, Mylan has expanded its global footprint of EpiPen to over 60 countries.
Market Key Trends
One of the key trends in the global epinephrine autoinjector market is the increasing availability of generic and affordable alternatives to EpiPen. For instance, in 2018, Teva launched its generic epinephrine autoinjector that provided an affordable alternative. Similarly, Impax Laboratories and Adamis Pharmaceuticals have also launched generic epinephrine autoinjectors. This increase in availability of more affordable options is expected to boost market growth by improving accessibility.
Porter’s Analysis
Threat of new entrants: New companies find it difficult to enter the epinephrine autoinjector market due to the large investments required in R&D and manufacturing of emergency medical devices.
Bargaining power of buyers: Individual consumers have little bargaining power, however large buyers like hospitals can negotiate lower prices.
Bargaining power of suppliers: A few major companies are engaged in manufacturing of autoinjectors and associated components which gives them considerable bargaining power.
Threat of new substitutes: There is no clinically viable substitute for epinephrine in the emergency treatment of allergic reactions.
Competitive rivalry: Major companies compete on the basis of product differentiation, innovative features and expanding geographic footprint.
Geographical Regions
North America dominates the global epinephrine autoinjector market currently accounting for over 40% of the total market value due to high incidence of food and drug allergies in the region.
Asia Pacific is poised to register the fastest growth during the forecast period driven by increasing patient awareness, rising prevalence of anaphylaxis, and growing access to emergency epinephrine devices in major markets like India and China.
